- Home
- XGN vs BRNS Comparison
XGN vs BRNS Comparison
Compare XGN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | BRNS |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 30.4M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XGN | BRNS |
|---|---|---|
| Price | $7.35 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $8.86 | $4.00 |
| AVG Volume (30 Days) | ★ 274.7K | 88.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.59 | $0.51 |
| 52 Week High | $12.23 | $1.83 |
Technical Indicators
Market Signals| Indicator | XGN | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 60.28 |
| Support Level | $4.08 | $0.65 |
| Resistance Level | $7.99 | $0.74 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 10.60 | 66.07 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.